- Crystal structures of intermediates in a new synthesis of antitumor drug cabozantinib
-
The heterocyclic antitumor drug cabozantinib was synthesized by condensation of 4-(6,7-dimethoxyquinolin-4-yloxy)aniline and methyl 1-(4-fluorophenylcarbamoyl)cyclopropanecarboxylate in the presence of two equivalents of sodium methoxide and azeotropic re
- Laus, Gerhard,Schreiner, Erwin,Nerdinger, Sven,Kahlenberg, Volker,Wurst, Klaus,Vergeiner, Stefan,Schottenberger, Herwig
-
-
Read Online
- Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors
-
While the treatment of gastrointestinal stromal tumors (GISTs) has been revolutionized by the application of targeted tyrosine kinase inhibitors capable of inhibiting KIT-driven proliferation, diverse mutations to this kinase drive resistance to establish
- Kettle, Jason G.,Anjum, Rana,Barry, Evan,Bhavsar, Deepa,Brown, Crystal,Boyd, Scott,Campbell, Andrew,Goldberg, Kristin,Grondine, Michael,Guichard, Sylvie,Hardy, Christopher J.,Hunt, Tom,Jones, Rhys D. O.,Li, Xiuwei,Moleva, Olga,Ogg, Derek,Overman, Ross C.,Packer, Martin J.,Pearson, Stuart,Schimpl, Marianne,Shao, Wenlin,Smith, Aaron,Smith, James M.,Stead, Darren,Stokes, Steve,Tucker, Michael,Ye, Yang
-
-
Read Online
- Synthesis method of cabozantinib and intermediate thereof
-
The invention provides a synthesis method of cabozantinib and an intermediate thereof, and belongs to the field of medicinal chemistry. According to the invention, cyclopropane-1,1-dicarboxylic acid amine is used as a key intermediate, and reacts with sub
- -
-
Paragraph 0113-0117
(2021/02/24)
-
- Preparation method of cabozantinib or salt thereof
-
The invention relates to a preparation method of cabozantinib or a salt thereof, which comprises the following steps: taking a compound shown as a formula I and 1-((4-fluorophenyl)carbamoyl)cyclopropanecarboxylic acid as raw materials, conducting reacting
- -
-
Paragraph 0036-0038; 0045-0046
(2021/06/22)
-
- PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF
-
Disclosed are a kinase inhibitor and a pharmaceutical composition comprising the kinase inhibitor. The kinase inhibitor comprises a compound as represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug
- -
-
Paragraph 0067-0068
(2021/10/22)
-
- PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE
-
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.
- -
-
Paragraph 0414-0415; 0417
(2021/04/02)
-
- COMPOUNDS AND METHODS OF USE
-
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.
- -
-
Paragraph 0205-0208; 0210
(2021/09/04)
-
- Preparation method of cabozantinib defluorination impurity
-
The invention discloses a preparation method of a cabozantinib defluorination impurity. The method comprises the following steps: preparing an intermediate 1, preparing 4-chloro-6, 7-dimethoxyquinoline, preparing an intermediate 2, and removing fluorine i
- -
-
Paragraph 0019; 0035-0036
(2020/08/25)
-
- Synthesis method of cabozantinib dimer
-
The invention discloses a synthesis method of a cabozantinib dimer. The method comprises the following steps: preparation of 4-chloro-6,7-dimethoxyquinoline, preparation of an intermediate 1, and preparation of a cabozantinib dimer impurity; and preparati
- -
-
Paragraph 0022-0023; 0030-0031
(2020/07/28)
-
- Preparation method for cabozantinib degradation impurity without p-fluoroaniline
-
The invention discloses a preparation method for a cabozantinib degradation impurity without p-fluoroaniline. The method comprises the following steps: preparation of 4-chloro-6,7-dimethoxyquinoline;preparation of an intermediate 1; and preparation of p-f
- -
-
Paragraph 0017; 0022-0023; 0029-0030
(2020/09/09)
-
- Method of Treating Cancer and Bone Cancer Pain
-
This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in a
- -
-
Paragraph 0119; 0121-0123
(2020/08/25)
-
- Method of Treating Cancer
-
This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.
- -
-
Paragraph 0126; 0129-0132
(2020/11/30)
-
- Novel substituted pyrazolo [1, 5-a] pyrimidine compound and preparation method and application thereof
-
The invention provides a novel substituted pyrazolo [1, 5-a]pyrimidine compound and a preparation method and application thereof, and particularly relates to a pyrazolo [1, 5-a]pyrimidine-containing quinoline derivative shown as a general formula (I) and pharmaceutically acceptable salts thereof, and substituent groups X, Ar and A have meanings given in the specification. The invention also relates to a compound represented by the general formula (I), wherein the compound has a strong c-Met kinase inhibition effect. The invention also relates to application of the compound and the pharmaceutically acceptable salt thereof in preparation of drugs for treating and/or preventing diseases caused by abnormal high expression of c-Met kinase, especially application in preparation of drugs for treating and/or preventing cancers.
- -
-
-
- COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS
-
The present invention relates to compounds that modulate cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemoinvasion, by modulating protein kinase enzymatic activity, and compositions thereof, and methods of using such compounds.
- -
-
-
- Preparation method of cabozantinib (S)-malate and intermediate thereof
-
The invention relates to a preparation method of cabozantinib (S)-malate and an intermediate thereof. The method includes: taking 4-chloro-6, 7-dimethoxyquinoline (I) as the starting raw material, andconducting substitution, condensation and salt formatio
- -
-
Paragraph 0072-0077
(2019/07/04)
-
- Preparation method of Cabozantinib
-
The invention belongs to the field of pharmaceutical chemistry, and relates to a preparation method of Cabozantinib. The preparation method comprises following steps: 4-halogenated-6, 7-dimethoxyquinoline is reacted with 4-aminophenol to prepare a compoun
- -
-
Paragraph 0034-0038; 0039-0041; 0043-0045
(2019/08/12)
-
- Preparation method of multi-receptor tyrosine kinase inhibitor and intermediate thereof
-
The invention relates to a preparation method of cabozantinib. The method includes: taking 4-chloro-6, 7-dimethoxyquinoline (I) as the starting raw material, and conducting substitution and condensation to obtain cabozantinib. Compared with other preparat
- -
-
Paragraph 0041-0043
(2019/07/04)
-
- Preparation method of Cabozantinib
-
The invention relates to a preparation method of Cabozantinib, and belongs to the field of pharmaceutical chemistry. The Cabozantinib compound is prepared through two steps. The preparation method comprises following steps: 1, a compound III and a compoun
- -
-
Paragraph 0027-0039
(2019/08/12)
-
- Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)- N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors
-
Starting from our previously developed c-KIT kinase inhibitor CHMFL-KIT-8140, through a type II kinase inhibitor binding element hybrid design approach, we discovered a novel c-KIT kinase inhibitor compound 18 (CHMFL-KIT-64), which is potent against c-KIT wt and a broad spectrum of drug-resistant mutants with improved bioavailability. 18 exhibits single-digit nM potency against c-KIT kinase and c-KIT T670I mutants in the biochemical assay and displays great potencies against most of the gain-of-function mutations in the juxtamembrane domain, drug-resistant mutations in the ATP binding pocket (except V654A), and activation loops (except D816V). In addition, 18 exhibits a good in vivo pharmacokinetic (PK) profile in different species including mice, rats, and dogs. It also displays good in vivo antitumor efficacy in the c-KIT T670I, D820G, and Y823D mutant-mediated mice models as well as in the c-KIT wt patient primary cells which are known to be imatinib-resistant. The potent activity against a broad spectrum of clinically important c-KIT mutants combining the good in vivo PK/pharmacodynamic properties of 18 indicates that it might be a new potential therapeutic candidate for gastrointestinal stromal tumors.
- Liu, Qingsong,Wu, Yun,Wang, Beilei,Wang, Junjie,Qi, Shuang,Zou, Fengming,Qi, Ziping,Liu, Feiyang,Liu, Qingwang,Chen, Cheng,Hu, Chen,Hu, Zhenquan,Wang, Aoli,Wang, Li,Wang, Wenchao,Ren, Tao,Cai, Yujiao,Bai, Mingfeng,Liu, Jing
-
p. 6083 - 6101
(2019/08/02)
-
- Antitumor compound used as AXL inhibitor and application of antitumor compound
-
The invention discloses a compound shown in a general formula (I) or pharmaceutically acceptable salt of the compound and preparation methods of the compound and the salt, and further discloses pharmaceutical composition containing the compound and an application of the compound and the pharmaceutical composition in preparation of an AXL inhibitory drug. The AXL inhibitory drug is used for treating tumor, nephropathy, immune system disease or circulatory system disease.
- -
-
Paragraph 0083-0085
(2019/10/23)
-
- AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
The present invention relates to an improved process for the preparation of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide compound of formula-1 which is represented by the following structural formula:
- -
-
Page/Page column 11
(2019/12/28)
-
- Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors
-
Deregulation of receptor tyrosine kinase c-Met has been reported in human cancers and is considered as an attractive target for small molecule drug discovery. In this study, a series of 4-phenoxyquinoline derivatives bearing sulfonylurea moiety were designed, synthesized and evaluated for their c-Met kinase inhibition and cytotoxicity against tested four cell lines in vitro. The pharmacological data indicated that most of the tested compounds showed moderate to significant potency as compared with foretinib, with the most promising compound 13x (c-Met kinase IC50 = 1.98 nM) demonstrated relatively good selectivity versus 10 other tyrosine kinases and remarkable cytotoxicities against HT460, MKN-45, HT-29 and MDA-MB-231 with IC50 values of 0.055 μM, 0.064 μM, 0.16 μM and 0.49 μM, respectively. The preliminary structure activity relationships indicated that a sulfonylurea moiety as linker as well as mono-EGWs (such as R1 = 4-F) on the terminal phenyl rings contributed to the antitumor activity.
- Nan, Xiang,Jiang, Yi-Fan,Li, Hui-Jing,Wang, Jun-Hu,Wu, Yan-Chao
-
p. 2801 - 2812
(2019/05/15)
-
- Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia
-
FMS-like tyrosine kinase 3 (FLT3) was an important therapeutic target in acute myeloid leukemia (AML). We synthesized two series of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives possessing the semicarbazide moiety and 2,2,2-trifluoro-N,N′-dimeth
- Xu, Qiaoling,Dai, Baozhu,Li, Zhiwei,Xu, Le,Yang, Di,Gong, Ping,Hou, Yunlei,Liu, Yajing
-
-
- Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors
-
Aurora kinases are known to be overexpressed in various solid tumors and implicated in oncogenesis and tumor progression. A series of nicotinamide derivatives were synthesized and their biological activities were evaluated, including kinase inhibitory act
- Qi, Baohui,Xu, Xingwei,Yang, Ying,He, Huan,Yue, Xupeng
-
p. 3825 - 3835
(2019/07/16)
-
- 4-phenoxy quinoline sulfonylurea compound, intermediate for synthesizing compound, and preparation method and application of compound
-
The invention relates to the technical field of preparation of medical compounds, in particular to a 4-phenoxy quinoline sulfonylurea compound, an intermediate, and a preparation method and application of the compound. The compound is characterized in tha
- -
-
-
- Preparation method of cabozantinib
-
The invention relates to a preparation method of cabozantinib, and particularly relates to the synthesis of cabozantinib through four steps of hydroxyl protection reaction, coupling reaction, reduction reaction and condensation reaction, using 5,6-dimetho
- -
-
-
- Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
-
Based on the cabozantinib scaffold, novel c-Met inhibitors were rationalized from the limited knowledge of structure-activity relationships for the quinoline 6-position. Emphasis was given to modifications capable of engaging in additional polar interacti
- Lien, Vegard Torp,Pettersen, Solveig,Haugen, Mads Haugland,Olberg, Dag Erlend,M?landsmo, Gunhild M.,Klaveness, Jo
-
-
- ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF
-
Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.
- -
-
-
- COMBINATIONS OF CABOZANTINIB AND ATEZOLIZUMAB TO TREAT CANCER
-
This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
- -
-
Paragraph 0081; 0082; 0085; 0086; 0087; 0089
(2018/08/12)
-
- Method for preparing antitumor drug cabozantinib intermediate by solid base catalysis
-
The invention belongs to the technical field of catalytic materials, and in particular relates to a method for preparing an antitumor drug cabozantinib intermediate by solid base catalysis. Accordingto the method provided by the invention, Zr is used as a
- -
-
Page/Page column 8-11
(2018/11/03)
-
- LIQUID DOSAGE FORMS TO TREAT CANCER
-
This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.
- -
-
Paragraph 00163; 00164; 00167-00168; 00169-00171
(2019/01/06)
-
- Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors
-
The overexpression of AXL kinase has been described in many types of cancer. Due to its role in proliferation, survival, migration, and resistance, AXL represents a promising target in the treatment of the disease. In this study we present a novel compound family that successfully targets the AXL kinase. Through optimization and detailed SAR studies we developed low nanomolar inhibitors, and after further biological characterization we identified a potent AXL kinase inhibitor with favorable pharmacokinetic profile. The antitumor activity was determined in xenograft models, and the lead compounds reduced the tumor size by 40% with no observed toxicity as well as lung metastasis formation by 66% when compared to vehicle control.
- Szabadkai, István,Torka, Robert,Garamv?lgyi, Rita,Baska, Ferenc,Gyulavári, Pál,Boros, Sándor,Illyés, Eszter,Choidas, Axel,Ullrich, Axel,órfi, László
-
p. 6277 - 6292
(2018/07/05)
-
- Preparation method of cabozantinib
-
The invention relates to a preparation method of cabozantinib. The method comprises the following steps: taking 5,6-dimethoxy-4-hydroxyquinoline, TsCl, fluoronitrobenzene, and 1-(4-fluorophenyl)amino-carbonyl cyclopropane carboxylic acid as raw materials, and performing steps of a hydroxy protection reaction, a coupling reaction, a reduction reaction, and a condensation reaction to obtain the cabozantinib. The preparation method of cabozantinib has the advantages of high yield, low cost, less three wastes, easy operation, and safety, and is suitable for industrialization.
- -
-
-
- One-step synthesis of [18F]cabozantinib for use in positron emission tomography imaging of c-Met
-
Cabozantinib is an FDA-approved kinase inhibitor for the treatment of medullary thyroid cancer and advanced renal cell carcinoma, which exerts its therapeutic effect by inhibiting, among others, the tyrosine kinase c-Met. Noninvasive imaging techniques are becoming increasingly important clinically to ensure drug efficacy, staging, monitoring, and patient stratification. PET isotope labelled tyrosine kinase inhibitors have, for the same reason, potential as PET tracers for imaging of various cancers. On the basis of cabozantinib, we synthesized the novel boronic acid pinacol ester 4 as a labelling precursor, where the boronic ester moiety replaces the fluorine native to this kinase inhibitor. By this, we wanted to explore whether recently developed Cu-mediated fluorination methods are adaptable to more complex substrates and thereby provide easy access to [18F]cabozantinib directly. Hydrolysis was implemented before preparative purification due to challenges with on-column hydrolysis of the precursor 4, and [18F]cabozantinib was obtained in ≥99% radiochemical purity and in 2.8?±?0.05% (n?=?4) isolated decay corrected yield in a synthesis time of 90?minutes. The molar activity of representative batches was determined to be 17?±?8?GBq/μmol.
- Lien, Vegard Torp,Klaveness, Jo,Olberg, Dag Erlend
-
-
- Cabozantinib preparation method
-
The invention discloses a cabozantinib preparation method. The target product cabozantinib is prepared by performing five-step reaction on diethyl malonate, 4-fluoroaniline, 4-chloro-6,7-dimethoxyquinoline, 4-aminophenol, 1,2-dibromoethane and the like us
- -
-
Paragraph 0040; 0041; 0042; 0043; 0058; 0059; 0070; 0071
(2017/08/28)
-
- METHOD FOR TREATING OSTEOPOROSIS
-
This invention is directed to the treatment of osteoporosis using N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
- -
-
Paragraph 0116
(2017/06/21)
-
- Anti-tumor therapeutic drug card abundantly for Nepal synthetic method
-
The invention discloses a synthesis method of an antineoplastic drug cabozant inib. 4-(6,7-dimethoxyquinolin-4-oxygroup)-phenyl amine and 1-((4-fluorophenyl) carbamoyl) cyclopropane acyl halide and an acid-binding agent are adopted for reaction in an orga
- -
-
Paragraph 0040-0042; 0045; 0046
(2017/08/24)
-
- Quinoline multi-target kinase inhibitor with antitumor activity and preparation method thereof
-
The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.
- -
-
Paragraph 0116; 0117; 0118
(2016/10/08)
-
- A tyrosine kinase inhibitor and wherein the intermediate preparation method
-
The invention relates to a preparation method for a tyrosine kinase inhibitor and a midbody thereof. According to the method, a compound 1,1-cyclopropane dicarboxylic acid diester is taken as a raw material, and 1-((4-((6,7-dimethoxy quinoline-4-yl) oxy)
- -
-
Paragraph 0115; 0116; 0117
(2016/10/10)
-
- DRUG COMBINATIONS TO TREAT MULTIPLE MYELOMA
-
This invention relates to the combination of a C-Met inhibitor and a proteasome inhibitor to treat cancer, particularly multiple myeloma.
- -
-
Paragraph 00111; 00112; 00114
(2016/03/19)
-
- METHOD OF PREPARING FLUORINE-18 LABELED CABOZANTINIB AND ITS ANALOGS
-
The present invention relates to a method of preparing Cabozantinib (Cyclopropane- 1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylo]amide (4-fluoro- phenyl)amide) and 18F labeled Cabozantinib.
- -
-
Paragraph 0096; 0097
(2016/03/29)
-
- Methods of Using C-Met Modulators
-
Methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments are described, wherein R1 is halo; R2 is halo; and Q is CH or
- -
-
Paragraph 0095; 0097
(2016/03/05)
-
- Quinoline derivatives (by machine translation)
-
A compound represented by general formula (I) (I) has a strong Axl inhibiting activity by introducing a distinctive bicyclic structure in which a saturated carbocyclic ring is fused to a pyridone ring, and thus may be used as a therapeutic agent for Axl related diseases such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, cancer such as glioma, kidney disease, immune system disease, and circulatory system disease.
- -
-
Paragraph 0820; 0821; 0822; 0823; 0824
(2016/10/08)
-
- 2,3-dimethyl-6-urea -2H-indazoles and its preparation method and application
-
The invention discloses a 2, 3-dimethyl-6-urea-2H-indazole compound shown by the following general formula (I), medicinal salt or a solvent compound thereof, wherein Ar is substituted or unsubstituted phenyl or aromatic matrix. The invention also discloses a preparation method and application of the compound. The compound can regulate signal transduction of tyrosine kinase, inhibit bad cellular proliferation, and particularly has obvious curative effect for tumors.
- -
-
Paragraph 0213-0216
(2016/10/09)
-
- C-met modulator pharmaceutical compositions
-
Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.
- -
-
Page/Page column 31; 32
(2016/10/10)
-
- METHOD OF TREATING LUNG ADENOCARCINOMA
-
This invention is directed to the treatment of cancer in a patient, particularly a patient with lung adenocarcinoma, and more particularly a patient with SLC34A2-ROS1, CD74-ROS1, or FIG-ROSl fusion-positive non-small cell lung cancer, with an inhibitor of
- -
-
Paragraph 00263; 00265
(2015/11/16)
-
- CABOZANTINIB DOSAGE FORM AND USE IN THE TREATMENT OF CANCER
-
This invention relates to a dosage form of cabozantinib and a method of employing the dosage form to treat cancer.
- -
-
Paragraph 00197
(2014/10/18)
-
- DRUG COMBINATIONS TO TREAT CANCER
-
This invention relates to the combination of cabozantinib and abiraterone to treat cancer, particularly castration resistant prostate cancer.
- -
-
Paragraph 0077; 0078; 0080; 0081; 0082
(2014/10/18)
-
- PROCESS FOR PREPARING QUINOLINE DERIVATIVES
-
A process for preparing a compound of Formula I is disclosed, comprising the steps: wherein: R1 is halo; R2 is halo; R3 is (C1-C6)alkyl or (C1-C6)alkyl optionally substituted wit
- -
-
Paragraph 0061
(2013/05/09)
-